Firstly, a comprehensive review of the literature and company websites revealed a lack of specific CHOP inhibitors, impeding their clinical application and translational research aimed at reducing CHOP levels to alleviate cognitive deficits associated with chronic pain. This evidence concerns the gene DDIT3 and Cognitive impairment.